Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.

CourtDistrict Court, W.D. Texas
DecidedFebruary 22, 2022
Docket1:20-cv-00783
StatusUnknown

This text of Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc. (Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc., (W.D. Tex. 2022).

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

HOMELAND INSURANCE § COMPANY OF NEW YORK, § Plaintiff, § § v. § CIVIL NO. 1-20-CV-783-RP

§ CLINICAL PATHOLOGY § LABORATORIES, INC. and SONIC § HEALTHCARE USA, INC., § Defendants.

REPORT AND RECOMMENDATION OF THE UNITED STATES MAGISTRATE JUDGE

TO: THE HONORABLE ROBERT PITMAN UNITED STATES DISTRICT JUDGE Before the Court are Plaintiff Homeland Insurance Company of New York’s Opposed Motion to Deny or Delay Consideration of Defendant’s Motion for Summary Judgment under Rule 56(d), filed under seal on November 1, 2021 (Dkt. 74); Defendants’ Response to Plaintiff’s Rule 56(d) Motion, filed November 9, 2021 (Dkt. 79) (sealed); Plaintiff’s Reply, filed November 16, 2021 (Dkt. 86) (sealed); and Defendants’ Sur-Reply, filed with leave of Court on February 3, 2022 (Dkt. 96). On February 2, 2022, the District Court referred the Rule 56(d) Motion and related filings to the undersigned Magistrate Judge for Report and Recommendation, pursuant to 28 U.S.C. § 636(b)(1)(B), Federal Rule of Civil Procedure 72, and Rule 1(d) of Appendix C of the Local Rules of the United States District Court for the Western District of Texas. 1 I. General Background As the District Court has stated: This case is about an insurance coverage dispute. Dkt. 55 at 1. Homeland Insurance Company of New York (“Homeland”) provides insurance coverage to Defendants Clinical Pathology Laboratories, Inc. (“CPL”) and Sonic Healthcare USA, Inc. (“Sonic USA”) (collectively, “Defendants”), which provide cervical cytology laboratory screening

services to detect cervical cancer. Around March 2010, as part of a national program in Ireland called CervicalCheck, the National Screening Service of Ireland (“NSS”) entered into contracts with two Irish companies to provide screening services for cervical cancer. The contracts identified CPL, in Austin, Texas, as the laboratory that would read the cancer screening slides. Also in 2010, CervicalCheck began an audit process called Cancer Audit Reviews (“CARs”), which reviewed women’s screening history after they developed cervical cancer to determine whether any slides in previous screenings had been misread. Around 2016, the NSS changed its protocol to require CARs results where slides had been misread to be reported to the patients’ physicians. Before 2016, Homeland insured Defendants only for claims made inside the United States.

Around 2015 and 2016, Homeland informed CPL and Defendants’ broker that there was no insurance coverage for a claim about misread slides because the claim was made outside the United States. Later in 2016, Defendants sought to expand coverage, in relevant part, to include claims made outside the United States against Defendants. Homeland agreed to the requested expanded coverage for the 2016-17 insurance policy (“2016 Policy”), allegedly conditioned on a July 27, 2016 letter (“2016 Letter”) provided by Stephen Shumpert, CPL’s President and Director and Sonic USA’s Chief Executive Director and Director, stating that, on behalf of the insureds, they were not aware of any potential claims against the insureds. Homeland alleges that the assurances in this letter were false because at least some of the original five defendants in this case were aware of potential claims based on misread slides. Defendants’ insurance coverage later was extended to 2017-18 (“2017 Policy”). In 2018, a lawsuit was filed on behalf of “Ms. S” based on a misread slide (the “Ms. S claim”). CPL settled the matter in October 2019 and sought reimbursement from Homeland in May 2020, alleging that the claim is covered under the 2017 Policy. Homeland denied the claim in July 2020.

Homeland filed this lawsuit on July 24, 2020. In its First Amended Complaint, Homeland named both Defendants and three foreign defendants: MedLab Pathology; Sonic Healthcare (Ireland), Limited; and Sonic Healthcare, Limited. Dkt. 21. Pursuant to the Agreed Scheduling Order issued by the Court on May 19, 2021, discovery was to be completed by January 21, 2022. Dkt. 32 ¶ 7. All five original defendants moved to dismiss the foreign defendants for lack of personal jurisdiction under Federal Rule of Civil Procedure 12(b)(2) and to dismiss all of the claims against Defendants under Rule 12(b)(6) for failure to state a claim. Dkt. 24. In an Amended Order issued August 4, 2021, the District Court granted the motion to dismiss the claims against the three foreign

defendants for lack of personal jurisdiction under Rule 12(b)(2). Dkt. 55 at 16. The Court also granted in part and denied in part the motion to dismiss Homeland’s claims. Id. On August 17, 2021, Homeland filed a Second Amended Complaint against Defendants, asserting claims for (1) declaratory judgment that there is no coverage for the Ms. S claim, three other specific claims, or any additional ongoing claims under the 2017 Policy; (2) breach of warranty based on the 2016 Letter; (3) reformation of the 2016 and 2017 Policies to reflect that the 2016 Letter was meant to exclude certain claims from coverage; and (4) promissory estoppel that Defendants cannot contend the 2016 Letter was not incorporated into the policies. Dkt. 56. On September 28, 2021, the Court issued an Amended Agreed Scheduling Order, extending the deadline to complete discovery until March 18, 2022. Dkt. 59 ¶ 9. On October 14, 2021, Defendants filed a 25-page motion for summary judgment on all of Homeland’s claims and several defenses.1 Dkt. 63. On November 1, 2021, Homeland filed a 25-page response to Defendants’ motion for summary judgment, attaching 293 pages of exhibits, as well as the instant Rule 56(d)

Motion. Dkts. 73, 74. Defendants filed a reply brief in support of their motion for summary judgment on November 9, 2021, and on February 11, 2022, the Court issued an Amended Agreed Scheduling Order extending the discovery deadline until September 30, 2022. Dkts. 81, 98. II. Plaintiff’s Rule 56(d) Motion Homeland asks the Court to deny or defer Defendants’ motion for summary judgment pursuant to Rule 56(d). Defendants respond that their summary judgment motion turns on questions of law, asserting that: “Homeland’s Rule 56(d) motion fails because none of the facts Homeland seeks to adduce can influence the outcome of Defendants’ summary judgment motion, which is predicated on the insurance policies, the pleadings, Texas law, and the Court’s prior rulings—not issues of fact.” Dkt. 77 (redacted) at 14.

A. Legal Standard The Federal Rules of Civil Procedure give district courts the power to grant summary judgment motions before the parties have completed discovery. MDK Sociedad De Responsabilidad Limitada v. Proplant Inc., --- F.4th ----, No. 21-20207, 2022 WL 391951, at *3 (5th Cir. Feb. 9, 2022) (citing Rule 56(b) (“Unless a different time is set by local rule or the court orders otherwise, a party may file a motion for summary judgment at any time until 30 days after the close of all

1 Defendants’ motion for summary judgment is not referred to the undersigned Magistrate Judge. discovery.”) and Mendez v. Poitevent, 823 F.3d 326, 336 (5th Cir. 2016) (“Rule 56 does not require that any discovery take place before summary judgment can be granted.”) (citation omitted)).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Raby v. Livingston
600 F.3d 552 (Fifth Circuit, 2010)
Thomas v. Arn
474 U.S. 140 (Supreme Court, 1986)
Bobby Battle v. U.S. Parole Commission
834 F.2d 419 (Fifth Circuit, 1987)
American Family Life Assurance v. Glenda Biles, et
714 F.3d 887 (Fifth Circuit, 2013)
Juan Mendez, Sr. v. Taylor Poitevent
823 F.3d 326 (Fifth Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/homeland-insurance-company-of-new-york-v-clinical-pathology-laboratories-txwd-2022.